Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

3 International Stocks for Retirees
3 International Stocks for Retirees
Retirees these days are living longer than ever before. That means there's a need to not only sustain your income with dividends, but also to grow your nest egg by investing in high-quality....
What's Behind GW Pharmaceuticals' 6.4% Gain in October?
What's Behind GW Pharmaceuticals' 6.4% Gain in October?
Shares of GW Pharmaceuticals plc (NASDAQ: GWPH), a company developing an epilepsy drug derived from its cannabinoid product platform, tacked on another 6.4% in October according to data from....
GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug
GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug
This year has been a real seesaw for shareholders of GW Pharmaceuticals (NASDAQ: GWPH). Lately, that seesaw is tipping up slightly, following news that a cannabidiol-based drug candidate the....
True or False: Republicans Support Legalizing Marijuana?
True or False: Republicans Support Legalizing Marijuana?
Chances are that you'd struggle to find an industry within the U.S. that's growing at a faster and more consistent pace than legal marijuana.Colorado, one of the eight states that's legalized....
3 High-Yield International Stocks
3 High-Yield International Stocks
Because of the generally more favorable corporate tax rates abroad, international stocks can, on occasion, offer enormous yields that are sustainable in the long term. The international investing....
Ionis Pharmaceuticals Tumbles on Biogen's Miss: Buy or Sell?
Ionis Pharmaceuticals Tumbles on Biogen's Miss: Buy or Sell?
Ionis Pharmaceuticals (NASDAQ: IONS) lost 11% of its market value after commercialization partner Biogen (NASDAQ: BIIB) reported third-quarter sales of its drug, Spinraza, that failed to match....
3 Arguments for and Against Legalizing Marijuana
3 Arguments for and Against Legalizing Marijuana
There's arguably no industry in the U.S. that's growing at a faster, more consistent pace than legal marijuana. Marijuana Business Daily's latest report, "Marijuana Business Factbook 2017,"....
Why Marijuana Stocks Won't Pay a Dividend, Even if They're Profitable
Why Marijuana Stocks Won't Pay a Dividend, Even if They're Profitable
There aren't too many industries that can grow at 20%-plus a year over the next five years, but marijuana could be one of them. Cannabis research firm ArcView believes the legal North American pot....
3 Small-Cap Biotech Stocks That Could Be Big Winners in 2018
3 Small-Cap Biotech Stocks That Could Be Big Winners in 2018
Small-cap biotech stocks, or companies with valuations ranging from $300 million to $2 billion, can generate truly astonishing returns on capital in exceptionally short periods of time. Several of....
Why MannKind, Nutanix, and Smith & Nephew Jumped Today
Why MannKind, Nutanix, and Smith & Nephew Jumped Today
The stock market ticked up on Tuesday, with the Dow and other major benchmarks posting gains of 0.1% to 0.3%. Concerns about the fate of the tax reform proposal in Washington continued to have....
What's Behind AstraZeneca's September Rebound?
What's Behind AstraZeneca's September Rebound?
After a tough couple of months, British pharma giant AstraZeneca (NYSE: AZN) actually saw its shares rise by a healthy 12.5% last month, according to data from S&P Global Market Intelligence.....
Caveat Emptor When Buying High-Yield Drug Stocks
Caveat Emptor When Buying High-Yield Drug Stocks
Income investors seemingly have hundreds of stocks to choose from that currently pay a dividend. The telecom and utility sectors often generate some of the most robust payouts for investors, with....
12 Flu Season Facts You Need to Know
12 Flu Season Facts You Need to Know
Fall is officially here, and that usually means three things: pumpkin-spiced everything is back in style, our lush trees are about to become leafless sticks, and that sniffle and cough could be....
3 Top Marijuana Stocks to Buy This Fall
3 Top Marijuana Stocks to Buy This Fall
Marijuana stocks weren't all that hot in the first half of 2017. The situation began to turn around for several leading marijuana stocks in the summer, though. What's the outlook for fall? Pretty....
5 Marijuana Stocks Overflowing With Cash
5 Marijuana Stocks Overflowing With Cash
Marijuana may be illegal at the federal level, but that hasn't slowed growth of the drug one iota within the U.S. or North America. In June, Mexico fully legalized medical cannabis, and right now....
Jeff Sessions May Soon Have a Green Light to Wage War on Medical-Marijuana Businesses
Jeff Sessions May Soon Have a Green Light to Wage War on Medical-Marijuana Businesses
The U.S. marijuana industry has witnessed a number of major changes over the past two-plus decades. Since 1996, when California became the first state to legalize medical cannabis for....
Investors' Biggest Worry About GW Pharmaceuticals Could Be the Biotech's Ace in the Hole
Investors' Biggest Worry About GW Pharmaceuticals Could Be the Biotech's Ace in the Hole
GW Pharmaceuticals' (NASDAQ: GWPH) stock soared more than 60% last year. So far in 2017, though, shares of the cannabinoid-focused biotech are down rather than up. One possible reason behind GW....
3 Things Amgen Inc.'s Management Just Said That You'll Want to Know
3 Things Amgen Inc.'s Management Just Said That You'll Want to Know
It's been a great 2017 for Amgen (NASDAQ: AMGN) shareholders so far. Amgen stock is up close to 30%. The company announced several positive developments from its pipeline. Still, though, some....
The 5 Worst Reasons to Buy Marijuana Stocks
The 5 Worst Reasons to Buy Marijuana Stocks
Chances are you'd struggle to find an industry that's been stronger over the trailing one-year period than legal marijuana. Cannabis research firm ArcView pegged North American legal weed growth....
Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc
Big drugmaker. High dividend yield. Promising new products. All three apply to AbbVie Inc. (NYSE: ABBV). They also all apply to GlaxoSmithKline plc (NYSE: GSK). But while AbbVie stock has achieved....
Here's Why Shire PLC Stock Fell 10% in August
Here's Why Shire PLC Stock Fell 10% in August
Shares of Shire PLC (NASDAQ: SHPG), a biopharmaceutical company that focuses on treatments for rare diseases, fell 9.94% in August, according to data from S&P Global Market Intelligence.....
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Last week, Gilead Sciences (NASDAQ: GILD) generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma (NASDAQ: KITE). On Wednesday, several of the company's top....
GlaxoSmithKline Is Wasting Money Paying a Dividend
GlaxoSmithKline Is Wasting Money Paying a Dividend
As a general rule, I love companies that pay big dividends -- and British pharmaceutical giant GlaxoSmithKline (NYSE: GSK) pays some of the best dividends on the planet. That said, there's one....
Say What? 2 New Studies Find Little Evidence That Marijuana Helps Treat Chronic Pain and PTSD
Say What? 2 New Studies Find Little Evidence That Marijuana Helps Treat Chronic Pain and PTSD
When it comes to growth industries, essentially nothing tops legal marijuana. According to cannabis research firm ArcView, the legal cannabis market in North America is slated to grow from $6.9....
Why Intra-Cellular Therapies Is Skyrocketing Today
Why Intra-Cellular Therapies Is Skyrocketing Today
Intra-Cellular Therapies (NASDAQ: ITCI), a clinical-stage biopharma focused on diseases of the central nervous system, rose more than 26% as of 11:35 a.m. EDT Wednesday. The big jump came in....